Karim Iskander

1.3k total citations
30 papers, 795 citations indexed

About

Karim Iskander is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Karim Iskander has authored 30 papers receiving a total of 795 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Hematology and 14 papers in Oncology. Recurrent topics in Karim Iskander's work include Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (6 papers). Karim Iskander is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (13 papers) and Cancer Treatment and Pharmacology (6 papers). Karim Iskander collaborates with scholars based in United States, France and Greece. Karim Iskander's co-authors include Ola Landgren, Anil K. Jaiswal, Roberto Barrios, Marilène Paquet, Delwin J. Long, Cory Brayton, Amos Gaikwad, Hermann Einsele, Robert Z. Orlowski and Hossein Borghaei and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Karim Iskander

29 papers receiving 787 citations

Peers

Karim Iskander
Comparison fields: 5 of 91
  • Molecular Biology 499
  • Oncology 317
  • Hematology 308
  • Immunology 95
  • Toxicology 92
Replace Kristen Lantz with:
Kristen Lantz United States
David L. Dai United States
Filippa Pettersson Canada
Natalie E. Simpson United States
Quan Lin China
Enrique Poradosu United States
Olesya Vakhrusheva Germany
Maria Teresa Rizzo United States
Anita L. Korapati United States
Anastasia Parton Switzerland
Kristen Lantz United States View profile →
Citations per field, relative to Karim Iskander
Karim Iskander · 1×
Citations per year, relative to Karim Iskander
Karim Iskander · 1×

Countries citing papers authored by Karim Iskander

Since Specialization
Citations

This map shows the geographic impact of Karim Iskander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim Iskander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim Iskander more than expected).

Fields of papers citing papers by Karim Iskander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karim Iskander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim Iskander. The network helps show where Karim Iskander may publish in the future.

Co-authorship network of co-authors of Karim Iskander

This figure shows the co-authorship network connecting the top 25 collaborators of Karim Iskander. A scholar is included among the top collaborators of Karim Iskander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karim Iskander. Karim Iskander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies
2022 ·Leukemia & lymphoma ·Ola Landgren, Dickran Kazandjian, Murielle Roussel, Jagoda Jasielec, Dominik Dytfeld, (unknown), (unknown), Karim Iskander, (unknown), Andrzej Jakubowiak
2
2
Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials
2020 ·Cancer Medicine ·Philippe Moreau, Keith Stewart, Meletios Α. Dimopoulos, David S. Siegel, Thierry Façon, James R. Berenson, Noopur Raje, Jesús G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, María‐Victoria Mateos
13
3
The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
2020 ·Cancer ·Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, Marion Subklewe, Gail J. Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M. Kantarjian
162
4
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
2019 ·Leukemia ·Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim Iskander, Khalid Mezzi, David S. Siegel
42
5
Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.
2019 ·Journal of Clinical Oncology ·Andreas Viardot, Georg Heß, Ralf C. Bargou, Nicholas Morley, Giuseppe Gritti, Karim Iskander, David Cohan, Alicia Zhang, Janet Franklin, Luke Coyle
1
6
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
2018 ·Clinical Lymphoma Myeloma & Leukemia ·Xavier Leleu, Thomas G. Martin, Hermann Einsele, Roger M. Lyons, Brian G.M. Durie, Karim Iskander, Sikander Ailawadhi
17
7
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
2018 ·Blood ·Meletios Α. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Karim Iskander, Zhao Yang, Amy Kimball, Khalid Mezzi, Heinz Ludwig, Rubén Niesvizky
29
8
Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study
2018 ·Blood ·Ola Landgren, David S. Siegel, Daniel Auclair, Ajai Chari, Michael Boedigheimer, (unknown), Khalid Mezzi, Karim Iskander, Andrzej Jakubowiak
6
9
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
2018 ·Blood Advances ·Ajai Chari, A. Keith Stewart, Stuart D. Russell, Philippe Moreau, Joerg Herrmann, José Banchs, Roman Hájek, John D. Groarke, Alexander R. Lyon, (unknown), Sunhee Ro, Mei Huang, Karim Iskander, Daniel J. Lenihan
50
10
Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines
2018 ·Blood ·Philippe Moreau, A. Keith Stewart, Antonio Lazzaro, Meletios Α. Dimopoulos, Michèle Cavo, Sikander Ailawadhi, Karim Iskander, Mei Huang, Anita Zahlten‐Kumeli, María‐Victoria Mateos
1
11
Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial
2018 ·Blood ·Pieter Sonneveld, Sonja Zweegman, Michèle Cavo, Kazem Nasserinejad, (unknown), Luděk Pour, Sandra Croockewit, Paolo Corradini, Francesca Patriarca, (unknown), (unknown), Annemiek Broyl, Monique C. Minnema, (unknown), Karim Iskander, Mario Boccadoro
23
12
Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study
2017 ·Blood ·Meletios Α. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Zhao Yang, Amy Kimball, Karim Iskander, Khalid Mezzi, Heinz Ludwig, Rubén Niesvizky
2
13
Demographic and Clinical Characteristics of Multiple Myeloma (MM) Patients Treated with Carfilzomib-Based Regimens in a Real World Setting
2017 ·Blood ·(unknown), Winifred Werther, Karim Iskander, Michael L. Gruber, Khalid Mezzi
4
14
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
2017 ·Leukemia ·Parameswaran Hari, MV Mateos, Rafat Abonour, Stefan Knop, Jack W. Singer, Heinz Ludwig, Kevin Song, Roman Hájek, Philippe Moreau, David S. Siegel, Shibao Feng, Mihaela Obreja, Sanjay Aggarwal, Karim Iskander, Hartmut Goldschmidt
16
15
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
2017 ·Journal of Internal Medicine ·Ola Landgren, Karim Iskander
111
16
Rates of peripheral neuropathy (PN) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM) treated with carfilzomib vs comparators in pivotal phase III trials.
2017 ·Journal of Clinical Oncology ·Rubén Niesvizky, Vânia Hungria, Joy Ho, Aleksandr Suvorov, Darrell White, Dina Ben‐Yehuda, Lifen Zhou, Karim Iskander, Laura Rosiñol
3
17
Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure
2016 ·Blood ·Jesús G. Berdeja, Robert M. Rifkin, Roger M. Lyons, Hui Yang, (unknown), Sanjay Aggarwal, Karim Iskander, James R. Berenson
1
18
NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity
2006 ·Journal of Biological Chemistry ·Karim Iskander, Jessica Li, Shuhua Han, Biao Zheng, Anil K. Jaiswal
57
19
Deficiency of NRH:Quinone Oxidoreductase 2 Increases Susceptibility to 7,12-Dimethylbenz( a )anthracene and Benzo( a )pyrene-Induced Skin Carcinogenesis
2004 ·Cancer Research ·Karim Iskander, Marilène Paquet, Cory Brayton, Anil K. Jaiswal
46
20
Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity
2002 ·Journal of Biological Chemistry ·Delwin J. Long, Karim Iskander, Amos Gaikwad, Meral J. Arin, Dennis R. Roop, Richard J. Knox, Roberto Barrios, Anil K. Jaiswal
94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristen Lantz Breakdown of academic impact, for papers by David L. Dai Breakdown of academic impact, for papers by Filippa Pettersson Breakdown of academic impact, for papers by Natalie E. Simpson Breakdown of academic impact, for papers by Quan Lin Breakdown of academic impact, for papers by Enrique Poradosu Breakdown of academic impact, for papers by Olesya Vakhrusheva Breakdown of academic impact, for papers by Maria Teresa Rizzo Breakdown of academic impact, for papers by Anita L. Korapati Breakdown of academic impact, for papers by Anastasia Parton
Rankless by CCL
2026